Biogen Inc. Stock

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2024-07-19 EDT 5-day change 1st Jan Change
226.4 USD +0.51% Intraday chart for Biogen Inc. -1.59% -12.51%
Sales 2024 * 9.52B 13.08B Sales 2025 * 9.53B 13.08B Capitalization 32.96B 45.26B
Net income 2024 * 1.86B 2.56B Net income 2025 * 2.18B 2.99B EV / Sales 2024 * 3.78 x
Net Debt 2024 * 3.03B 4.16B Net Debt 2025 * 262M 360M EV / Sales 2025 * 3.49 x
P/E ratio 2024 *
18.1 x
P/E ratio 2025 *
15.6 x
Employees 7,570
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.81%
More Fundamentals * Estimated data
Dynamic Chart
1 day+0.51%
1 week-1.59%
Current month-2.34%
1 month+0.36%
3 months+16.47%
6 months-9.43%
Current year-12.51%
More quotes
1 week
220.81
Extreme 220.81
231.27
1 month
220.02
Extreme 220.02
238.00
Current year
189.44
Extreme 189.44
268.30
1 year
189.44
Extreme 189.44
280.42
3 years
187.16
Extreme 187.16
351.86
5 years
187.16
Extreme 187.16
468.55
10 years
187.16
Extreme 187.16
480.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 22-11-13
Director of Finance/CFO 60 20-08-14
Chief Operating Officer - 14-12-31
Members of the board TitleAgeSince
Director/Board Member 75 09-12-31
Director/Board Member 70 19-06-18
Chairman 64 10-01-02
More insiders
Date Price Change Volume
24-07-19 226.4 +0.51% 851,787
24-07-18 225.2 -1.35% 856,347
24-07-17 228.3 +1.47% 949,485
24-07-16 225 +1.55% 1,006,178
24-07-15 221.6 -3.69% 1,381,797

Delayed Quote Nasdaq, July 19, 2024 at 04:00 pm

More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
226.4 USD
Average target price
281.8 USD
Spread / Average Target
+24.45%
Consensus